Other Pigmentary Disorders in Darker Skin Types
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Heather Woolery-Lloyd, director of the Skin of Color Division for the University of Miami Department of Dermatology. There’s more to pigmentary disorders than melasma and vitiligo. Watch as Dr. Woolery-Lloyd outlines disorders of hyperpigmentation and hypopigmentation. Learn why time matters in treating lichen planus …
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Heather Woolery-Lloyd, director of the Skin of Color Division for the University of Miami Department of Dermatology. There’s more to pigmentary disorders than melasma and vitiligo. Watch as Dr. Woolery-Lloyd outlines disorders of hyperpigmentation and hypopigmentation. Learn why time matters in treating lichen planus … Continue reading "Other Pigmentary Disorders in Darker Skin Types"
Which of the following is least likely to be associated with the condition depicted in the image?
A. Insulin-dependent diabetes
B. Pernicious anemia
C. Pseudotumor cerebri
D. Hashimoto's thyroiditis
E. Grave's disease
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Iltefat Hamzavi, dermatologist with Henry Ford Health and associate professor of dermatology at Wayne State University School of Medicine. Dr. Hamzavi addresses how to diagnose and treat hypopigmentation, a catch-all for pigmentary conditions where the pigment is not too dark or complete … 
The operational wavelength of the most common laser used to treat the disorder depicted in this image is:
A. 1064 nm
B. 308 nm
C. 595 nm
D. 755 nm
E. 532 nm
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … 